Background:  Psoriasis is a chronic, proliferative, and inflammatory skin disorder that manifests as erythematous plaques coated in silvery scales, most often on the body's extensor surfaces, scalp, and lumbosacral area. Psoriasis individuals may potentially benefit from the antioxidant properties of SUA. Some evidence of colchicine's effectiveness in treating psoriasis has been gathered. Objective: To compare the serum uric acid level in psoriasis vulgaris individuals with that of healthy controls and to evaluate the effect of the addition of colchicine to the ordinary treatment of psoriasis on the level of serum uric acid and the degree of improvement of psoriasis. Patients and Methods: This prospective case-control research included 51 individuals with psoriasis, and conducted at outpatient clinic of the Dermatology, Andrology, and STDs Department at Mansoura University Hospitals. Results: There was a statistically significant variance among the patients concerning PASI score after treatment and uric acid level after treatment, while there was no statistically significant variance regarding PASI score before treatment and baseline uric acid. Non-smoking and receiving colchicine were associated with a better PASI score in univariable analysis. However, in multivariable analysis, receiving colchicine was considered a predictor of a better PASI score. Conclusion: Hyperuricemia was detected in psoriasis vulgaris cases, which showed improvement after the addition of colchicine to the treatment of hyperuricemia. Elevated serum uric acid levels didn't affect psoriasis severity. While receiving colchicine was considered a predictor of a better PASI score.